Enzootic Calf Pneumonia

Enzootic calf pneumonia, also known as bovine respiratory disease (BRD) complex in calves, is a multifactorial, contagious respiratory syndrome primarily affecting calves between 3 weeks and 6 months of age, particularly in intensive rearing systems. It is characterized by inflammation of the bronchi, bronchioles, and pulmonary parenchyma, often with a cranioventral distribution of lung consolidation. The disease results from the interaction of environmental stressors, viral infections, and secondary bacterial invasion, leading to significant morbidity, mortality, and economic losses. In dairy calves, it is a leading cause of poor growth, increased age at first calving, and premature culling. In beef calves, it is the most common cause of morbidity and mortality in the post-weaning period, especially in feedlots. The disease is often classified by the predominant etiological agent (viral, bacterial, or mycoplasmal) and by the age of the calf (neonatal, pre-weaning, post-weaning).

Enzootic calf pneumonia is a polymicrobial disease. Primary viral agents include Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza-3 virus (PI-3), Bovine Herpesvirus-1 (BHV-1, causing infectious bovine rhinotracheitis), Bovine Viral Diarrhea Virus (BVDV), Bovine Coronavirus, and Bovine Adenovirus. These viruses damage the respiratory epithelium, impair mucociliary clearance, and suppress local immune responses, predisposing to secondary bacterial invasion. Primary bacterial agents include Mannheimia haemolytica (serotype A1 and A6), Pasteurella multocida (serotype A and B), Histophilus somni, and Trueperella pyogenes. Mycoplasma bovis is a common and important pathogen, often causing chronic, caseonecrotic bronchopneumonia and arthritis. Mycoplasma dispar and Ureaplasma diversum may also be involved. Bacterial virulence factors include leukotoxins (M. haemolytica), capsular polysaccharides, adhesins, and proteases. M. bovis produces biofilms and has immunomodulatory properties, leading to chronic infection. Environmental factors such as poor ventilation, high humidity, ammonia buildup, overcrowding, and temperature fluctuations are critical in the etiology, as they impair respiratory defenses and increase pathogen load.

Enzootic calf pneumonia occurs worldwide and is most prevalent in dairy calves housed in groups, especially in poorly ventilated barns, and in beef calves after weaning and transport to feedlots. Morbidity rates can range from 10% to 40% in affected herds, with mortality rates of 5% to 20% in severe outbreaks. The disease is most common in calves aged 3 to 8 weeks, but can occur up to 6 months. Risk factors include failure of passive transfer (serum IgG < 10 g/L), colostrum management, age at grouping, group size, stocking density, ventilation rate, temperature fluctuations, and concurrent infections (e.g., coccidiosis, cryptosporidiosis). Seasonality is observed with peaks in autumn and winter in temperate regions, associated with increased housing and viral circulation. Economic losses arise from treatment costs, mortality, reduced weight gain, increased labor, and long-term effects on lung function and carcass quality. In dairy heifers, pneumonia in the first 6 months can reduce first-lactation milk yield by up to 5% and increase age at first calving.

The pathophysiology of enzootic calf pneumonia begins with viral infection of the upper and lower respiratory tract, causing epithelial necrosis, loss of cilia, and increased mucus production. This impairs mucociliary clearance and allows bacteria to colonize the lower airways. Bacterial proliferation leads to the release of virulence factors, such as M. haemolytica leukotoxin, which destroys alveolar macrophages and neutrophils, causing an intense inflammatory response. This results in increased vascular permeability, exudation of fibrin and protein into alveoli, and formation of fibrinous bronchopneumonia. The inflammatory cascade involves pro-inflammatory cytokines (TNF-α, IL-1, IL-8), leading to recruitment of neutrophils, which release reactive oxygen species and proteases, further damaging lung tissue. In chronic cases, especially with M. bovis, there is development of caseonecrotic lesions, bronchiolitis obliterans, and fibrosis. Systemic effects include fever, toxemia, and in severe cases, acute respiratory distress syndrome (ARDS) and sepsis. The cranioventral distribution of lesions is due to gravitational and aerodynamic deposition of pathogens.

Intrinsic factors include young age (immature immune system), failure of passive transfer (serum IgG < 10 g/L), genetic susceptibility (e.g., certain breeds like Holstein may be more susceptible), and concurrent diseases (e.g., bovine viral diarrhea virus infection causing immunosuppression). Extrinsic factors are numerous: inadequate colostrum management (delayed, insufficient, or poor-quality colostrum), poor housing conditions (inadequate ventilation, high humidity, ammonia > 25 ppm, drafts, temperature fluctuations), overcrowding (air space < 10 m³ per calf), poor hygiene (dirty bedding, contaminated feeding equipment), nutritional deficiencies (selenium, vitamin E, copper, zinc), stress from weaning, transport, dehorning, castration, and commingling of calves from different sources. Management practices such as all-in/all-out vs. continuous flow, and lack of vaccination programs also contribute.

Clinical signs vary from acute to chronic. Early signs include depression, reduced appetite, fever (rectal temperature > 39.5°C), nasal discharge (serous to mucopurulent), ocular discharge, and increased respiratory rate. As disease progresses, coughing becomes prominent, especially when calves are exercised. Auscultation of the lungs reveals increased bronchovesicular sounds, crackles, wheezes, and in severe cases, areas of consolidation with absent sounds. Calves may exhibit abdominal breathing, open-mouth breathing, and cyanosis in severe cases. Chronic cases show poor growth, rough hair coat, and persistent cough. In feedlot calves, the disease may be subclinical, with only reduced weight gain. Some calves develop complications such as otitis media (head tilt, ear droop), arthritis (especially with M. bovis), and meningitis. A scoring system (e.g., the Wisconsin Calf Respiratory Scoring Chart) is used to assess severity based on rectal temperature, cough, nasal discharge, eye discharge, and ear position.

Differential diagnoses include: 1) Infectious bovine rhinotracheitis (IBR) - caused by BHV-1, characterized by severe upper respiratory signs, tracheitis, and sometimes conjunctivitis; diagnosis by virus isolation or PCR. 2) Bovine respiratory syncytial virus (BRSV) infection - acute onset, severe dyspnea, and emphysema; diagnosis by serology or PCR. 3) Bovine viral diarrhea virus (BVDV) - may cause respiratory signs but also diarrhea, immunosuppression; diagnosis by antigen ELISA or PCR. 4) Mycoplasma bovis pneumonia - chronic, caseonecrotic lesions, often with arthritis; culture or PCR. 5) Pasteurellosis (Mannheimia haemolytica) - acute fibrinous pneumonia, often with toxemia; culture. 6) Aspiration pneumonia - history of improper feeding, lesions in the right cranial lung lobe; radiography. 7) Congestive heart failure - may cause pulmonary edema, but also jugular distension, peripheral edema; echocardiography. 8) Lungworm (Dictyocaulus viviparus) - parasitic bronchitis, eosinophilia, larvae in feces. 9) Tuberculosis - chronic, granulomatous lesions; tuberculin test. 10) Pulmonary abscesses - secondary to septicemia; ultrasonography.

The diagnostic approach begins with a thorough herd history and physical examination of affected calves. Individual calf assessment includes rectal temperature, respiratory rate, auscultation, and clinical scoring. If pneumonia is suspected, a complete blood count (CBC) and serum biochemistry may be performed, but are not always diagnostic. For herd-level diagnosis, nasal swabs or bronchoalveolar lavage (BAL) samples can be collected for viral and bacterial identification using PCR, virus isolation, or culture. Serology (paired samples) can confirm viral infections. Thoracic ultrasonography is a valuable tool to detect lung consolidation, pleural effusion, and abscesses. Radiography is less commonly used but can show cranioventral alveolar patterns. Necropsy of affected calves is essential for definitive diagnosis and to identify the primary pathogens. The algorithm should include assessment of passive transfer (serum IgG or total protein), environmental assessment (ventilation, stocking density), and review of vaccination and management protocols.

Hematology may show leukocytosis with neutrophilia and a left shift in bacterial pneumonia, or leukopenia in viral infections. Fibrinogen levels are often elevated (> 5 g/L). Serum biochemistry may reveal hypoxemia (PaO2 < 80 mmHg) and hypercapnia (PaCO2 > 45 mmHg) on blood gas analysis. Acute phase proteins, such as haptoglobin and serum amyloid A, are increased. In chronic cases, anemia may be present. Bronchoalveolar lavage fluid analysis shows increased neutrophils and bacteria. Culture and sensitivity of BAL fluid or nasal swabs can identify bacterial pathogens. PCR panels for viral and bacterial agents are increasingly used. In cases of M. bovis, PCR is preferred due to slow growth. Serology for BRSV, PI-3, BHV-1, and BVDV can be performed on paired sera. For BVDV, antigen detection (ELISA or immunohistochemistry) on ear notch samples is used to identify persistently infected animals.

Thoracic ultrasonography is the most useful imaging modality in calves. It can be performed with a 5-7.5 MHz linear or convex probe. Findings include: 1) Anechoic areas representing fluid-filled alveoli (consolidation) with air bronchograms (hyperechoic lines). 2) Pleural effusion (anechoic space between lung and chest wall). 3) Abscesses (well-defined hypoechoic to hyperechoic areas with thick walls). 4) Rounded lung margins in chronic cases. Ultrasonography can also guide BAL or thoracocentesis. Radiography is less practical in the field but can show cranioventral alveolar patterns, air bronchograms, and in chronic cases, nodular lesions. Computed tomography (CT) is used in research settings. In cases of suspected lungworm, fecal examination for larvae is performed.

Cytology of BAL fluid typically shows a high percentage of neutrophils (> 50%) in bacterial pneumonia, with intracellular bacteria. In viral pneumonia, mononuclear cells may predominate. Histopathology of lung tissue at necropsy reveals: 1) In acute bacterial pneumonia: fibrinous bronchopneumonia with neutrophils, fibrin, and edema in alveoli. 2) In chronic M. bovis infection: caseonecrotic lesions with central necrosis surrounded by neutrophils and macrophages, and bronchiolitis obliterans. 3) In viral pneumonia: interstitial pneumonia with alveolar septal thickening, mononuclear infiltration, and hyaline membranes in severe cases. 4) In BRSV infection: necrotizing bronchiolitis and syncytial cells. Immunohistochemistry can identify specific viral or bacterial antigens.

Treatment should be initiated early and is based on antimicrobial therapy, anti-inflammatory drugs, and supportive care. Antimicrobial selection should be based on culture and sensitivity, but empirical therapy is often necessary. Common antimicrobials include: 1) Oxytetracycline (10-20 mg/kg IV or SC, q24h or q48h, long-acting formulations). 2) Tulathromycin (2.5 mg/kg SC, single dose). 3) Florfenicol (20 mg/kg IM or SC, q48h, two doses). 4) Ceftiofur (2.2 mg/kg SC or IM, q24h for 3-5 days). 5) Enrofloxacin (7.5-12.5 mg/kg SC, q24h, for 3-5 days; not recommended in calves due to cartilage damage, but used in some countries). 6) Ampicillin (10-20 mg/kg IM or SC, q12h). 7) Penicillin G procaine (20,000-40,000 IU/kg IM, q24h). Non-steroidal anti-inflammatory drugs (NSAIDs) are crucial to reduce fever and inflammation: flunixin meglumine (1.1-2.2 mg/kg IV, q24h for up to 3 days), meloxicam (0.5 mg/kg SC or PO, single dose), or ketoprofen (3 mg/kg IV or IM, q24h). Supportive care includes providing a clean, dry, well-ventilated environment, ensuring adequate nutrition and hydration, and in severe cases, oxygen therapy. Fluid therapy may be needed for dehydrated calves. In chronic cases, treatment may be prolonged and often unsuccessful.

The prognosis is good for calves with early, uncomplicated pneumonia and prompt treatment. However, it is guarded for calves with severe clinical signs, chronic infection, or complications such as M. bovis arthritis. Negative prognostic indicators include: age < 3 weeks, failure of passive transfer, severe respiratory distress (respiratory rate > 80 breaths/min, cyanosis), prolonged illness (> 7 days), and lack of response to initial antimicrobial therapy. Calves that recover may have permanent lung damage, leading to reduced growth and increased risk of future respiratory disease. In feedlot cattle, chronic pneumonia can lead to lung abscesses and reduced carcass value. Mortality rates can be high in severe outbreaks, especially in calves with concurrent viral infections.

After treatment, calves should be monitored daily for clinical improvement (temperature, respiratory rate, appetite, demeanor). Recheck auscultation and consider repeat ultrasonography after 7-14 days to assess resolution of consolidation. Calves that do not improve within 48-72 hours should be re-evaluated and antimicrobial therapy adjusted based on culture and sensitivity. For herd-level control, a comprehensive follow-up plan includes: 1) Review of colostrum management and passive transfer status. 2) Environmental assessment and improvement of ventilation, stocking density, and hygiene. 3) Vaccination protocols for dams and calves (e.g., intranasal BRSV/PI-3 vaccines). 4) Biosecurity measures to prevent introduction of new pathogens. 5) Monitoring of growth rates and respiratory disease incidence. 6) Necropsy of any fatalities to identify pathogens.

Pearls: 1) Early detection is key; use a standardized clinical scoring system. 2) Thoracic ultrasonography is more sensitive than auscultation for detecting consolidation. 3) NSAIDs are essential to control inflammation and fever. 4) In outbreaks, treat all calves in the affected group, not just those with clinical signs. 5) Ensure adequate colostrum intake within 2 hours of birth. 6) Use intranasal vaccines for rapid protection. Pitfalls: 1) Delaying treatment until severe clinical signs appear. 2) Using antimicrobials without considering culture and sensitivity, leading to resistance. 3) Neglecting environmental factors; treating calves while returning them to the same poor conditions. 4) Overlooking chronic M. bovis infections, which require prolonged treatment and may not respond to standard antimicrobials. 5) Using fluoroquinolones in calves due to potential cartilage damage. 6) Failing to monitor for complications like arthritis or otitis.

Based on Plumb's Veterinary Drug Handbook and AABP guidelines, the following protocols are recommended: 1) Tulathromycin (Draxxin): 2.5 mg/kg SC, single dose; meat withdrawal 18 days, milk withdrawal 0 days (not for lactating dairy). 2) Florfenicol (Nuflor): 20 mg/kg IM or SC, repeated at 48 hours; meat withdrawal 28 days, milk withdrawal 0 days. 3) Ceftiofur crystalline free acid (Excede): 6.6 mg/kg SC at base of ear, single dose; meat withdrawal 13 days, milk withdrawal 0 days. 4) Oxytetracycline (LA-200): 20 mg/kg IM or SC, single dose; meat withdrawal 28 days, milk withdrawal 96 hours. 5) Enrofloxacin (Baytril 100): 7.5-12.5 mg/kg SC, q24h for 3-5 days; meat withdrawal 22 days, milk withdrawal 0 days (not approved in some countries for calves). 6) Flunixin meglumine (Banamine): 1.1-2.2 mg/kg IV, q24h for up to 3 days; meat withdrawal 4 days, milk withdrawal 36 hours. 7) Meloxicam (Metacam): 0.5 mg/kg SC or PO, single dose; meat withdrawal 15 days, milk withdrawal 0 days. 8) Ketoprofen: 3 mg/kg IV or IM, q24h for up to 3 days; meat withdrawal 7 days, milk withdrawal 0 days. Always follow label directions and consult with a veterinarian for specific cases.

Key studies and consensus guidelines: 1) The Wisconsin Calf Respiratory Scoring Chart (McGuirk, 2008) is widely used for early detection. 2) A meta-analysis by Taylor et al. (2010) found that tulathromycin and florfenicol are effective for BRD treatment. 3) The AABP (American Association of Bovine Practitioners) has published guidelines on antimicrobial use in BRD, emphasizing the importance of culture and sensitivity. 4) Studies by Van der Fels-Klerx et al. (2001) and others have shown that failure of passive transfer is a major risk factor. 5) Research on BRSV vaccination has shown reduced severity of disease (e.g., Ellis et al., 2001). 6) The use of NSAIDs in combination with antimicrobials has been shown to improve recovery rates (e.g., Faji et al., 2016). 7) Long-term effects of calf pneumonia on growth and milk production have been documented in cohort studies (e.g., Bach et al., 2011). 8) The ECBHM (European College of Bovine Health Management) has published guidelines on respiratory disease management in calves.